证券代码：688065 证券简称：凯赛生物 公告编号：2025-058 上海凯赛生物技术股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 15 日 （二） 股东会召开的地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 145 | | --- | --- | | 普通股股东人数 | 145 | | 2、出席会议的股东所持有的表决权数量 | 471,687,692 | | 普通股股东所持有表决权数量 | 471,687,692 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 65.6080 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 65.6080 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field, which is seen as a new growth point that can drive industrial structure optimization and economic transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper provides an overview of the global biomanufacturing industry, including its development status and trends [5]. - It compares the biomanufacturing sectors of China and the United States, highlighting competitive dynamics [5]. - Future development trends in biomanufacturing are discussed, indicating potential growth areas [5]. Group 2: Policy Landscape - The report outlines major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. - It details foreign biomanufacturing industry policies and their implications for the sector [5]. - Domestic policies related to biomanufacturing are also analyzed, providing insights into regulatory frameworks [5]. Group 3: Industry Map and Applications - The white paper presents a comprehensive map of the Chinese biomanufacturing industry, identifying key players and their roles [5]. - It analyzes the biomanufacturing industry chain and key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5][6]. - Specific applications of biomanufacturing in various sectors are highlighted, showcasing its versatility and potential impact [5]. Group 4: Key Enterprises and Investment Landscape - The report identifies ten leading enterprises in the Chinese biomanufacturing industry, providing insights into their operations and market positions [6]. - It summarizes the strategic directions of 15 listed companies in synthetic biology, indicating their focus areas and growth strategies [6]. - The investment landscape for synthetic biology in China is examined, detailing funding trends and opportunities from 2024 to mid-2025 [6]. Group 5: Challenges and Recommendations - The white paper discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - It offers targeted policy recommendations to address these challenges, aiming to support the sustainable development of the biomanufacturing sector [6].

证券代码：688065 证券简称：凯赛生物 公告编号：2025-057 上海凯赛生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/22 司 | | ， | 由 | 公 | 原 | 控 | 股 | 股 | 东 | Cathay | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Industrial Biotech Ltd.提议 | | | | | | | | | | | | 回购方案实施期限 | 2024 年 月 日~2025 月 | 10 | 21 | | | 年 | 10 | 20 | 日 | | | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | | | | □用 ...

Core Viewpoint - Kaisa Biotech (688065.SH) announced a share buyback of 230,366 shares, representing 0.0319% of the total share capital, executed through the Shanghai Stock Exchange on September 30, 2025 [1] Summary by Category - **Share Buyback Details** - The buyback was conducted via centralized bidding [1] - The highest transaction price was 53.40 CNY per share, while the lowest was 44.08 CNY per share [1] - The total amount spent on the buyback was 10,497,716.71 CNY, excluding stamp duty and transaction commissions [1]

Core Viewpoint - Kaisa Biotech (688065.SH) announced a share buyback of 230,366 shares, representing 0.0319% of the total share capital, executed through the Shanghai Stock Exchange on September 30, 2025 [1] Summary by Categories - **Share Buyback Details** - The buyback was conducted via centralized bidding on the Shanghai Stock Exchange [1] - The highest transaction price was 53.40 CNY per share, while the lowest was 44.08 CNY per share [1] - The total amount spent on the buyback was 10,497,716.71 CNY, excluding stamp duty and transaction commissions [1]

Core Viewpoint - Shanghai Kasei Biotechnology Co., Ltd. has announced a share repurchase plan proposed by its original controlling shareholder, with a total repurchase amount expected to be between 10 million and 20 million yuan [1] Group 1: Share Repurchase Details - The share repurchase plan was approved by the board of directors on October 21, 2024, and will be implemented from October 21, 2024, to October 20, 2025 [1] - As of September 30, 2025, the company has repurchased a total of 230,366 shares, accounting for 0.0319% of the total share capital [1] - The total amount spent on repurchases so far is 10,497,716.71 yuan, with the actual repurchase price ranging from 44.08 yuan to 53.40 yuan per share [1] Group 2: Future Plans - The company will continue to advance the share repurchase as per regulations and will disclose information in a timely manner [1]

Core Viewpoint - The company, Kaisa Bio, announced its plan to utilize the shareholder meeting reminder service provided by Shanghai Stock Exchange Information Network Co., Ltd. to actively remind shareholders to participate in voting through smart SMS and other means [1] Group 1 - The company will delegate the task of sending meeting invitations and agenda information to each investor to Shanghai Stock Exchange Information [1]

上海凯赛生物技术股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688065 证券简称：凯赛生物 2025 年第三次临时股东会会议资料 中国·上海 二〇二五年十月十五日 上海凯赛生物技术股份有限公司 2025 年第三次临时股东会会议资料 目 录 | 上海凯赛生物技术股份有限公司 | 2025 年第三次临时股东会会议须知 1 | | --- | --- | | 上海凯赛生物技术股份有限公司 | 2025 年第三次临时股东会议程 3 | | 议案一：关于《公司 2025 | 年员工持股计划（草案）》及其摘要的议案 4 | | 议案二：关于《公司 2025 | 年员工持股计划管理办法》的议案 5 | | 议案三：关于授权董事会办理公司 | 2025 年员工持股计划相关事宜的议案 6 | 上海凯赛生物技术股份有限公司 2025 年第三次临时股东会会议资料 上海凯赛生物技术股份有限公司 上海凯赛生物技术股份有限公司 地址：中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 邮编：201203 电话：86-21-50801916 传真：86-21-50801386 网站：http://www.catha ...

为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股东 名册主动提醒股东参会投票，向每一位投资者主动推送股东会参会邀请、议案情 况等信息。投资者在收到智能短信后，可根据《上市公司股东会网络投票一键通 服务用户使用手册》（下载链接：https://vote.sseinfo.com/i/yjt_help.pdf）的提示 步骤直接投票，如遇拥堵等情况，仍可通过原有的交易系统投票平台和互联网投 票平台进行投票。 若广大投资者对本次服务有任何意见或建议，可通过邮件、投资者热线等方 式向公司反馈，感谢广大投资者对公司的关注与支持。 特此公告。 上海凯赛生物技术股份有限公司 董事会 证券代码：688065 证券简称：凯赛生物 公告编号：2025-056 上海凯赛生物技术股份有限公司 关于股东会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海凯赛生物技术股 ...

Group 1 - The company announced that as of the date of the announcement, the total amount of external guarantees provided by its non-wholly-owned subsidiaries is 500 million yuan, all of which are guarantees among non-wholly-owned subsidiaries [1] - For the year 2024, the company's revenue composition is as follows: synthetic biological materials industry accounts for 95.31%, while other businesses account for 4.69% [1] - The current market capitalization of the company is 37.2 billion yuan [2]